Patients' Age Is Important When Setting Priorities

Published Jul 23, 2013
Tromsø, Norway - Several studies on priority setting preferences have shown that people think that differences both in patients’ ageand in remaining lifetime should be taken into account. Researchers from the University of Tromsø in Norway set out to determine what is more important: A patient’s age or their remaining lifetime if left untreated? Survey results from a Norwegian population sample provided strong support for the ‘fair innings’ argument that total lifetime inequalities should be reduced.  Differences in patients’ remaining lifetime without treatment did not matter, implying little support for the ‘end of life’ argument that a short life expectancy makes patients entitled to preferential treatment. When faced with pairwise choices between hypothetical patients, the majority of respondents would prioritise the younger patient even if the older patient had shorter remaining lifetime if left untreated. Professor Jan Abel Olsen, PhD, lead author on the study states, "It is more important to reduce inequalities in people's total lifetime than in their remaining lifetime."  The full study, “Priority Preferences: “End of Life” Does Not Matter, But Total Life Does,” is published inValue in Health.

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision-makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

For more information: www.ispor.org

Related Stories

Global Expert Panel Releases Good Practices Guidance for Developing or Updating Health Technology Assessment Guidelines

Jan 14, 2025

ISPOR announced today the publication of a tripartite task force report outlining good practices for developing or updating health technology assessment (HTA) guidelines.

Rethinking Value Assessment for Orphan Drugs

Dec 18, 2024

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced the publication of a special themed section of research papers that document challenges in rare disease evidence and economic evaluation and policy as well as ways in which the environment is evolving to address them.

ISPOR Releases Emerging Good Practices Guidance on Quantifying Specialized Knowledge in Healthcare

Nov 6, 2024

ISPOR announced the publication of an ISPOR Good Practices Report that identifies existing structured expert elicitation protocols that can support healthcare decision making and provides important insights on how to choose which protocols may be the most appropriate for different scenarios, such as time-constrained decisions, early-stage technology assessments, and public health policies.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×